Mizuho Maintains Outperform on Tarsus Pharmaceuticals, Lowers Price Target to $98

Benzinga Newsdesk www.benzinga.com Negative 93.4%

Neg 93.4% Neu 0% Pos 0%

Mizuho analyst Graig Suvannavejh maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Outperform and lowers the price target from $100 to $98.